Close Menu

Just days after announcing that it had settled a dispute over ownership of key intellectual property, Alnylam Pharmaceuticals disclosed that it has been sued by the University of Utah over the same IP.

According to an Alnylam filing with the US Securities and Exchange Commission, the university has alleged that one of its researchers, Brenda Bass, is the inventor of the technology covered in the so-called Tuschl-II patent estate.

Alnylam said it disagrees with the claims and intends to “defend the action vigorously.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
09
Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
24
Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.